Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Hikma Pharmaceuticals PLC (HIK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2,616.00 -28.00    -1.06%
26/07 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 131,898
  • Bid/Ask: 2,050.00 / 2,670.00
  • Day's Range: 2,610.00 - 2,640.00
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B0LCW083 
SEDOL:  B0LCW08
Hikma Pharma 2,616.00 -28.00 -1.06%
IndustryPharmaceuticals
SectorHealthcare
Employees

8600

Equity Type

ORD

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Contact Information

Phone 44 20 7399 2760
Fax 44 20 7399 2761

Top Executives

Name Age Since Title
Mazen Samih Talib Darwazah 62 2018 Executive Vice Chairman of the Board, President of MENA
Ali K. Al-Husry 63 2005 Non-Executive Director
Bassam Wael Rushdi Kanaan 56 2018 Executive Vice President - Corporate Development and M&A
Majda Labadi - 2018 Executive Vice President - Organisational Development
Susan Ringdal - 2020 Executive Vice President - Strategic Planning and Global Affairs
Said Samih Darwazah 63 2018 Executive Chairman of the Board
Khalid Nabilsi - 2011 Chief Financial Officer
Riad Mishlawi - 2018 President - Injectables
Peter Speirs - 2012 Company Secretary
Patrick Butler 60 2020 Senior Non-Executive Independent Director
Hussein Arkhagha - 2020 Chief Counsel
Pamela J. Kirby 67 2014 Non-Executive Independent Director
John J. Castellani 70 2016 Non-Executive Independent Director
Nina Henderson 70 2016 Non-Executive Independent Director
Brian Hoffman - 2017 President, US Generics Division
Sigurdur Olafsson 52 2018 Chief Executive Officer, Executive Director
Cynthia L. Schwalm 61 2019 Non-Executive Independent Director
Henriette Nielsen - 2018 Executive Vice President - Business Operations
Shahin Fesharaki - 2019 Chief Scientific Officer
Douglas Malcolm Hurt 64 2020 Non-Executive Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HIK Comments

Write your thoughts about Hikma Pharmaceuticals PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Adeel Khan
Adeel Khan Oct 09, 2020 16:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Touch 27 today
Adeel Khan
Adeel Khan Sep 12, 2020 14:06
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Next results will be super. Wait for it to hit £32 before end of this year
Jonny Tr
Jonny Tr Jun 17, 2020 15:58
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Aim listed Dark Matter Ltd, has more potential
Adeel Khan
Adeel Khan May 11, 2020 17:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will go up & up
Steve Oliphant
Steve Oliphant Dec 04, 2019 9:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not as stated here (March 11)
Steve Oliphant
Steve Oliphant Dec 04, 2019 9:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
Geoff Laidlaw
Geoff Laidlaw Jun 27, 2018 11:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any hint of progress on Advair will send this stock much higher still !
Geoff Laidlaw
Geoff Laidlaw May 18, 2018 21:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
Geoff Laidlaw
Geoff Laidlaw May 08, 2018 11:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Almost got me money back !!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email